Last reviewed · How we verify
Tazarotene 0.1% gel
Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and promote skin cell differentiation and turnover.
Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and promote skin cell differentiation and turnover. Used for Acne vulgaris, Plaque psoriasis, Photoaging and facial wrinkles.
At a glance
| Generic name | Tazarotene 0.1% gel |
|---|---|
| Also known as | Tazret gel 0.1%, TAZORAC® Gel 0.1%, TAZORAC® Cream 0.1%, Tazarotene, tazarac |
| Sponsor | Galderma R&D |
| Drug class | Retinoid |
| Target | Retinoid X receptor (RXR), Retinoid acid receptor (RAR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
As a third-generation retinoid, tazarotene selectively activates RXR and RAR nuclear receptors, which modulate transcription of genes involved in cell proliferation, differentiation, and inflammation. This leads to normalization of keratinization, reduced sebum production, and anti-inflammatory effects in the skin. The mechanism makes it effective for treating acne and psoriasis by promoting epidermal cell turnover and reducing comedone formation.
Approved indications
- Acne vulgaris
- Plaque psoriasis
- Photoaging and facial wrinkles
Common side effects
- Skin irritation (erythema, peeling, dryness)
- Photosensitivity
- Burning or stinging sensation
- Pruritus
Key clinical trials
- Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions (PHASE2)
- Excimer Laser With Topical Agents in Psoriasis Vulgaris (PHASE4)
- Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars (PHASE2, PHASE3)
- Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne (PHASE4)
- Efficacy of Tazarotene in Treatment of Verruca Plana (PHASE2)
- Dose Range Study of CD5789 in Acne Vulgaris (PHASE2)
- Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis (NA)
- Comparison Between Microneedling Daycare Procedure and Tazarotene 0.1% Gel Local Application in Acne Scarring (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tazarotene 0.1% gel CI brief — competitive landscape report
- Tazarotene 0.1% gel updates RSS · CI watch RSS
- Galderma R&D portfolio CI